SynthesisInternational journal of clinical practice2012
Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.
Synthesis in International journal of clinical practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.Journal of diabetes · 2025 · on this mapPooled it
- Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.Scientific reports · 2016 · on this mapPooled it
- Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).Cardiovascular diabetology · 2022Trial
- Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.The Journal of clinical endocrinology and metabolism · 2021Trial
- Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.Diabetes, obesity & metabolism · 2018Trial
- Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.Diabetes, obesity & metabolism · 2018 · on this mapTrial
- Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.Diabetes, obesity & metabolism · 2017Trial
- Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Sex- and Gender-Based Pharmacological Response to Drugs.Pharmacological reviews · 2021Article
- Sex Differences of the Diabetic Heart.Frontiers in physiology · 2021Review
- Gender differences in adverse event reports associated with antidiabetic drugs.Scientific reports · 2020Article
- Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Review
- Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.Diabetic medicine : a journal of the British Diabetic Association · 2018Review
- Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.Diabetes, obesity & metabolism · 2016Article
- Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes.Saudi medical journal · 2014Article
- Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.Advances in therapy · 2014Review
- Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine.PloS one · 2014Observational
- Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2014Review
- Exenatide extended-release; clinical trials, patient preference, and economic considerations.Patient preference and adherence · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatient numbers in individual diabetes trials are often too limited to assess the effect of a treatment by different patient characteristics, and meta-analyses often do not include patient-level data. The purpose of this pooled analysis was to evaluate the efficacy and tolerability of exenatide once weekly (EQW) in patients with type 2 diabetes grouped into subpopulations by key demographic characteristics.
methodsThis post hoc analysis included data from patients who received EQW in seven randomised, controlled phase 3 trials that were 24-30 weeks in duration. Patients were classified into subpopulations on the basis of their baseline age (< 65 or ≥ 65 years), gender (male or female), race (White, Black, Asian, Hispanic), duration of diabetes (< 10 years, ≥ 10 years) and body mass index (BMI; < 25, ≥ 25 to < 30, ≥ 30 to < 35, ≥ 35 to < 40 or ≥ 40 kg/m(2)).
resultsA total of 1719 patients were included in this analysis of patient subpopulations. All subpopulations experienced significant improvements from baseline in haemoglobin A1C, fasting glucose and body weight. Most subpopulations experienced significant improvements in blood pressure and lipid parameters. Overall, the most common AEs were hypoglycaemia (16.4% overall; 2.3% in patients not on concomitant sulfonylurea), nausea (14.7%), diarrhoea (10.9%) and nasopharyngitis (7.2%).
conclusionThese results show that the treatment of type 2 diabetes with EQW for 24-30 weeks was associated with significant improvements in glycaemic control and body weight, irrespective of age, gender, race, duration of diabetes or BMI. The most common adverse events were gastrointestinal in nature.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.